Stay updated on Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Clinical Trial page
- Check2 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check9 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check16 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check24 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check45 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check60 days agoChange DetectedThe webpage has been updated to include the study of Anaplastic Thyroid Cancer, with a new version indicating a collaboration with Merck Sharp & Dohme LLC. However, significant details about the study's goals and inclusion criteria have been removed.SummaryDifference44%
Stay in the know with updates to Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Clinical Trial page.